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Abstract 1	
Treatment of common bile duct disorders such as biliary atresia or ischaemic 2	
strictures is limited to liver transplantation or hepatojejunostomy due to the 3	
lack of suitable tissue for surgical reconstruction. Here, we report a novel 4	
method for the isolation and propagation of human cholangiocytes from the 5	
extrahepatic biliary tree and we explore the potential of bioengineered biliary 6	
tissue consisting of these extrahepatic cholangiocyte organoids (ECOs) and 7	
biodegradable scaffolds for transplantation and biliary reconstruction in vivo. 8	
ECOs closely correlate with primary cholangiocytes in terms of transcriptomic 9	
profile and functional properties (ALP, GGT). Following transplantation in 10	
immunocompromised mice ECOs self-organize into tubular structures 11	
expressing biliary markers (CK7). When seeded on biodegradable scaffolds, 12	
ECOs form tissue-like structures retaining biliary marker expression (CK7) 13	
and function (ALP, GGT). This bioengineered tissue can reconstruct the wall 14	
of the biliary tree (gallbladder) and rescue and extrahepatic biliary injury 15	
mouse model following transplantation. Furthermore, it can be fashioned into 16	
bioengineered ducts and replace the native common bile duct of 17	
immunocompromised mice, with no evidence of cholestasis or lumen 18	
occlusion up to one month after reconstruction. In conclusion, ECOs can 19	
successfully reconstruct the biliary tree following transplantation, providing 20	
proof-of-principle for organ regeneration using human primary cells expanded 21	
in vitro. 22	
 23	
  24	
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Disorders of the extrahepatic bile ducts carry considerable morbidity and 1	
mortality. Indeed, 70% of pediatric liver transplantations are performed to treat 2	
biliary atresia1, Primary Sclerosing Cholangitis (PSC) alone accounts for 5% 3	
of US liver transplantations2 and biliary complications are the leading cause of 4	
graft failure following deceased liver transplantation3,4. Treatment options 5	
remain limited5,6 due to the lack of healthy tissue that can be used to 6	
reconstruct and replace diseased bile ducts. In vitro expansion of native 7	
cholangiocytes could address this challenge and provide cells suitable for 8	
tissue engineering applications such as biliary reconstruction. However, the 9	
culture of primary biliary epithelium remains problematic7. Here we report a 10	
novel method for the isolation and propagation of primary human 11	
cholangiocytes from the extrahepatic biliary tree, compatible with regenerative 12	
medicine applications. The resulting Extrahepatic Cholangiocyte Organoids 13	
(ECOs) express key biliary markers such as Cytokeratin 7 (KRT7 or CK7), 14	
Cytokeratin 19 (KRT19 or CK19), Gamma Glutamyl-Transferase (GGT), 15	
Cystic fibrosis transmembrane conductance regulator (CFTR) and maintain 16	
their functional properties in vitro including Alkaline Phosphatase (ALP), GGT 17	
activity and responses to secretin and somatostatin. The potential of ECOs for 18	
tissue engineering and clinical applications is further illustrated by their 19	
capacity to populate biodegradable scaffolds, organize into a functional biliary 20	
epithelium and rescue a murine model of extrahepatic biliary injury (EHBI). 21	
 22	
Results 23	
Human extrahepatic cholangiocytes can be propagated as organoids 24	
7	
	
We first focused on identifying optimal conditions to isolate primary 1	
cholangiocytes from the biliary epithelium which forms a monolayer covering 2	
the luminal surface of the biliary tree8. We tested several approaches for 3	
recovering these cells and mechanical dissociation by brushing or scraping 4	
the bile duct lumen was associated with improved survival compared to 5	
enzymatic digestion (Figure 1a, Supplementary Fig 1a). Furthermore, the 6	
majority of the resulting cells co-expressed the biliary markers CK7 and CK19 7	
(94.6 ± 2.4%, SD; n=3); while no contamination from mesenchymal cell types 8	
was detected (Supplementary Fig 2). Consequently, mechanical dissociation 9	
constitutes the optimal method for harvesting extrahepatic cholangiocytes.  10	
To discern appropriate conditions for the maintenance and propagation of 11	
these cells, we optimized our recently established system for 3D culture of 12	
human induced pluripotent stem cell-derived intrahepatic cholangiocytes9,10. 13	
Screening of multiple growth factors known to support expansion of 14	
cholangiocytes and epithelial organoids11,12 (Supplementary Fig 1b-1c) 15	
identified that the combination of Epidermal Growth Factor (EGF), R-spondin 16	
and Dickkopf-related protein 1 (DKK-1) promoted the growth of primary 17	
cholangiocytes into organoids (Supplementary Fig 3a, 3b). Due to the 18	
paradoxical requirement for both a Wnt potentiator (R-spondin) and an 19	
inhibitor (DKK-1), we characterized the canonical and non-canonical/PCP Wnt 20	
pathway activity in ECOs. Our results demonstrate higher β-catenin 21	
phosphorylation in ECOs compared to cells treated with R-spondin but no 22	
DKK-1 (Supplementary Fig 1d-1e), signifying lower WNT canonical pathway 23	
activity in these cells. Furthermore ECOs exhibit higher Rho Kinase activity 24	
compared to cells treated with R-spondin but no DKK-1 (Supplementary Fig 25	
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1f), which could be consistent with enhanced non-canonical/PCP signaling in 1	
ECOs. Thus, it is possible that non-canonical Wnt signaling controls ECO 2	
expansion marking a notable difference with previous organoid culture 3	
conditions12. 4	
Under these conditions, we derived 8 different ECO lines (Supplementary 5	
Table 1) from a variety of deceased donors aged from 33 to 77 years. 6	
Notably, we obtained similar results by using cholangiocytes isolated from the 7	
gallbladder or by harvesting common bile duct cholangiocytes using an 8	
Endoscopic Retrograde Cholangio-Pancreatography (ERCP) brush instead of 9	
scrapping the lumen (Supplementary Fig 4). Consequently, ECOs can be 10	
derived from different areas of the extra-hepatic biliary tree and harvested 11	
using peri-operative (dissection and scrapping) or minimally invasive (ERCP 12	
brushings) approaches. 13	
 14	
ECOs maintain key biliary markers and function in culture  15	
The resulting cells were expanded in vitro for prolonged periods of time 16	
(Supplementary Fig 5a) while maintaining their genetic stability 17	
(Supplementary Fig 5b-5c). Electron microscopy revealed the presence of 18	
characteristic ultrastructural features including cilia, microvilli and tight 19	
junctions13 (Supplementary Fig 3c), while QPCR and immunofluorescence 20	
(IF) analyses established the expression of key biliary markers such as KRT7  21	
or CK7, KRT19 or CK19, Hepatocyte Nuclear Factor 1 beta (HNF1B), GGT, 22	
Secretin Receptor (SCTR), sodium-dependent bile acid transporter 23	
(ASBT/SLC10A2), CFTR and SRY-box 9 (SOX9)9 (Figure 1b-1c, 24	
9	
	
Supplementary Fig 4c-4d, 3d-3e). Of note, stem cell markers such as 1	
POU5F1 or OCT4, NANOG, prominin 1 (PROM1), leucine rich repeat 2	
containing G protein-coupled receptor (LGR) LGR-4/5/6; markers of non-3	
biliary lineages including albumin (ALB), α1-antitrypsin (SERPINA1 or A1AT), 4	
keratin 18 (KRT18), pancreatic and duodenal homeobox 1 (PDX1), insulin 5	
(INS) and glucagon (GCG); and EMT markers (vimentin (VIM), snail family 6	
transcriptional repressor 1 (SNAI1) and S100 calcium binding protein A4 7	
(S100A4) were not detected (Supplementary Fig 6a-6c). On the other hand, 8	
98.1% ± 0.9% (SD; n=3) of the cells co-expressed CK7 and CK19 following 9	
20 passages (Supplementary Fig 2) thereby confirming the presence of a 10	
near homogeneous population of cholangiocytes.  11	
Transcriptomic analyses (Figure 1d, Supplementary Fig 7, Supplementary 12	
Table 2) revealed that ECOs maintain a stable gene expression profile over 13	
multiple passages (Pearson correlation coefficient for Passage 1 (P1) vs. 14	
Passage 20 (P20) r=0.99, Supplementary Fig 7a-b), express key biliary 15	
markers (Supplementary Fig 7c) and cluster closely to freshly isolated 16	
cholangiocytes (Supplementary Fig 7d) (Pearson correlation coefficient for 17	
Primary Cholangiocytes (PCs) vs. Passage 20 (P20) r=0.92; Supplementary 18	
Fig 7b). Gene ontology analyses confirmed enrichment of pathways 19	
characteristic for the biliary epithelium (Supplementary Fig 7e). Considered 20	
collectively, these results demonstrate that primary cholangiocytes derived 21	
from the extrahepatic biliary tree can be expanded in vitro without losing their 22	
original characteristics. 23	
We then further characterized ECOs by focusing on their function following 24	
long term culture (20 passages). The biliary epithelium regulates the 25	
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homeostasis of bile through the transport of ions, water and bile acids8,14. The 1	
secretory capacity of ECOs was interrogated using Rhodamine-123, a 2	
fluorescent substrate for the cholangiocyte surface glycoprotein Multidrug 3	
Resistance protein-1 (MDR1)15,16 (Figure 2a-2c). Rhodamine-123 4	
accumulated in the ECO lumen only in the absence of the MDR-1 antagonist 5	
verapamil, thereby confirming active secretion through MDR-1 (Figure 2a-2c). 6	
Luminal extrusion of bile acids17 was also demonstrated by showing that the 7	
fluorescent bile acid Cholyl-Lysyl-Fluorescein (CLF) was actively exported 8	
from ECOs (Figure 2d-2f). Furthermore, ECO ALP and GGT activity was 9	
comparable to freshly plated primary cholangiocytes (Figure 2g-2h, 10	
Supplementary Fig 4e-4f). The response of ECOs to secretin and 11	
somatostatin was also assessed. Secretin promotes water secretion, 12	
distending the bile duct lumen, while somatostatin negates the effects of 13	
secretin18–20. Accordingly, organoids exposed to secretin increased their 14	
diameter compared to untreated controls, while somatostatin inhibited the 15	
effect of secretin (Figure 2i-2j). Our data, therefore, demonstrate that ECOs 16	
maintain their functional properties after long term culture. 17	
 18	
ECOs self-organize into tubular structures after transplantation 19	
These results prompted us to investigate the potential of ECOs for in vivo use, 20	
especially regenerative medicine applications. We first characterized the 21	
potential of ECOs for in vivo engraftment and survival by transplanting cells 22	
under the kidney capsule of NOD.Cg-Prkdcscid Il2rgtm1Wjl (NSG) mice 23	
(Supplementary Fig 8a) for 12 weeks21. ECOs successfully engrafted forming 24	
11	
	
tubular structures expressing biliary markers such as CK19 (Supplementary 1	
Fig 8b-d).  2	
Notably, no tumour formation or markers of differentiation to other lineages 3	
were detected (Supplementary Fig 8d). Thus, ECOs appear to maintain their 4	
basic characteristics even after prolonged engraftment in vivo under the 5	
kidney capsule.  6	
 7	
ECOs populate biodegradable scaffolds 8	
To assess the potential of ECOs for tissue engineering, we first interrogated 9	
their capacity for populating Polyglycolic Acid (PGA) biodegradable scaffolds 10	
commonly used to provide the structural and mechanical support required for 11	
tissue reconstruction22. Indeed, PGA is one of the most widely used synthetic 12	
polymers since it does not induce inflammatory responses in the surrounding 13	
tissue; it is biodegradable; and it is more flexible and easier to process 14	
compared to natural polymers such as collagen23. To facilitate tracking of the 15	
cells, ECOs expressing Green Fluorescent Protein (GFP) were generated 16	
through viral transduction (Supplementary Fig. 9a-9b). The resulting cells 17	
were seeded on PGA scaffolds, attached to the PGA fibers after 24-48 hours 18	
and continued to grow for 4 weeks until the scaffold was confluent (Figure 3a-19	
3d). Primary cholangiocytes plated in 2D conditions demonstrated limited 20	
expansion potential and failed to reach confluency when seeded on the 21	
scaffolds (Supplementary Fig 10a-b), suggesting that the proliferative capacity 22	
of ECOs is crucial for successful scaffold colonization. The populated PGA 23	
scaffolds (Figure 3b-3c), could easily be handled with forceps and divided into 24	
12	
	
smaller pieces with a surgical blade. Furthermore, the cells populating the 1	
scaffolds retained expression of biliary markers such as CK7 and CK19 2	
(Figure 3e-3f), demonstrated no evidence of epithelial–mesenchymal 3	
transition (EMT; Figure 3e, 3g) and maintained their functional properties 4	
including ALP and GGT activity (Figure 3h-3i). Therefore, ECOs can 5	
successfully populate PGA scaffolds, while maintaining their functionality and 6	
marker expression. 7	
 8	
ECO-populated scaffolds reconstruct the gallbladder wall 9	
Following these encouraging results, we decided to define the capacity of 10	
ECOs to repair the biliary epithelium. For that, we developed a mouse model 11	
of extrahepatic biliary injury (EHBI). More specifically, to simulate biliary tree 12	
wall defects requiring biliary reconstruction24, the biliary tree of healthy NSG 13	
mice was compromised through a longitudinal incision in the gallbladder wall 14	
(Figure 4a). The surgical defect in the gallbladder wall was subsequently 15	
repaired by transplanting bioengineered tissue into the injured animals, which 16	
was generated using GFP-expressing ECOs (see previous section; Figure 3). 17	
Acellular PGA scaffolds and scaffolds populated with GFP-expressing 18	
fibroblasts (Supplementary Fig 11a-11d) were used as a negative controls. 19	
Animals receiving acellular scaffolds died within 24 hours of the operation 20	
(Figure 4b) and post-mortem examination revealed yellow pigmentation of the 21	
peritoneal cavity and seminal vesicles  consistent with bile leak 22	
(Supplementary Fig 12a); while all animals in the fibroblast-scaffold group 23	
failed to reconstruct their gallbladder which was replaced by fibrotic tissue 24	
13	
	
incompatible with bile transport or storage (Supplementary Fig 13e-13g). In 1	
contrast, animals transplanted with scaffolds containing ECOs survived for up 2	
to 104 days without complications and were culled electively (Figure 4b). 3	
Notably, the reconstructed gallbladders in the ECO group were fully 4	
remodeled resembling the morphology of their native counterparts (Figure 4c, 5	
Supplementary Fig 12b). Histology (Figure 3d), IF and QPCR analyses of the 6	
ECO-reconstructed gallbladders (Figure 3e, Supplementary Fig 14c-14d) 7	
unveiled integration of GFP-positive ECOs expressing biliary markers, such 8	
as KRT19, KRT7, HNF1B, SOX9, CFTR and a human-specific epitope for 9	
Ku80 (Figure 4e, Supplementary Fig 12c). Of note, these IF analyses also 10	
showed the presence of mouse mesenchymal cells expressing vimentin and 11	
endothelial cells expressing CD31 in the reconstructed biliary epithelium 12	
suggesting that the scaffold is colonized by endogenous cells after 13	
transplantation (Supplementary Fig 12c). Furthermore, we also identified a 14	
population of GFP+/vimentin+/CK19- cells, suggesting that ECOs may also 15	
contribute to the scaffold stroma in vivo; possibly through EMT 16	
(Supplementary Fig 12c, 12e). The integrity of the reconstructed gallbladder 17	
lumen and its exposure to bile through continuity with the biliary tree were 18	
demonstrated using Magnetic Resonance Cholangio-Pancreatography 19	
(MRCP) imaging prior to removal of the organ and was further confirmed with 20	
FITC cholangiograms (Figure 4f-4g, Supplementary Fig 12f, Supplementary 21	
Video 1). Post mortem surgical examination and full body Magnetic resonance 22	
Imaging 104 days post transplantation revealed no evidence of tumor 23	
formation (Supplementary Fig 12f, Supplementary Video 2) while IF analyses 24	
revealed no GFP+ cells in the adjacent liver tissue (data not shown). On the 25	
14	
	
contrary, gallbladders reconstituted with fibroblasts controls exhibited 1	
obliteration of the gallbladder lumen (Supplementary Fig 11h-11i) and 2	
replacement of the lumen and biliary epithelium by fibroblasts expressing 3	
Fibroblast Specific Antigen S100A4 (Supplementary Fig. 11i-11j). Considered 4	
collectively, our findings demonstrate the capacity of ECOs to colonize their 5	
physiological niche and regenerate part of the biliary tree without any 6	
complications. 7	
 8	
ECOs on collagen scaffolds generate bioengineered bile ducts 9	
Reconstruction of the gallbladder wall provided proof-of-principle for the 10	
capacity of ECOs to regenerate the biliary epithelium after injury; however, the 11	
majority of extrahepatic bile duct disorders affect the common bile duct (CBD). 12	
Therefore, we focused on the generation of a tubular ECO-populated scaffold, 13	
which could be used for bile duct replacement surgery. The internal diameter 14	
of the mouse CBD is approximately 100μm with a wall thickness of less than 15	
50μm, which precluded the use of a PGA scaffold due to mechanical 16	
properties. Instead, we generated densified collagen tubular scaffolds (Figure 17	
5a-5b) which were populated with GFP-expressing ECOs (Figure 5c-5e). The 18	
use of densified collagen enabled the generation of constructs with an 19	
external diameter ranging from 250 to 600μm and adequate strength to 20	
maintain a patent lumen (Figure 5d). Notably, the cells populating the collagen 21	
scaffolds maintained expression of biliary markers such as KRT19, KRT7, 22	
HNF1B, SOX9 and CFTR (Figure 5f-5g) and exhibited GGT and ALP 23	
enzymatic activity (Figure 5h-5i). Primary epithelial cells of different origin 24	
15	
	
(human mammary epithelial cells; HMEC) failed to survive and adequately 1	
populate densified collagen tubes under the same conditions (Supplementary 2	
Fig. 13a). Moreover, plated HMECs failed to survive in a 10% (vol/vol) bile 3	
solution compared to ECOs (Supplementary Fig. 13b), further confirming that 4	
ECOs constitute the only cell type capable of generating bile resistant bio-5	
engineered bile ducts. Collectively, these results demonstrate the capacity of 6	
ECOs for populating tubular densified collagen scaffolds without losing their 7	
original characteristics.  8	
 9	
Bioengineered bile ducts replace the native mouse bile duct 10	
We then decided to explore the possibility to replace the native CBD of NSG 11	
mice with a bioengineered duct consisting of an ECO-populated densified 12	
collagen tube (Figure 5). A mid-portion of the native CBD was removed and 13	
an ECO-populated collagen tube was anastomosed end-to-end to the 14	
proximal and distal duct remnants (Figure 6a). Fibroblast populated tubes 15	
were used as a negative control. Biliary reconstruction was achieved in all 16	
animals transplanted with ECO-populated tubes (Figure 6b-6c, 17	
Supplementary Fig 14a-14d), which were followed up for up to a month post 18	
transplantation (Supplementary Fig 14d). Histology and IF and QPCR 19	
analyses (Figure 6d-6f, Supplementary Fig 14a-14b) revealed a patent lumen, 20	
with formation of a biliary epithelium by the transplanted GFP+ cells (Figure 21	
6e-6f, Supplementary Fig 14a-14b); confirmed the expression of biliary 22	
markers, such as KRT19, KRT7, HNF1B, CFTR, SOX9 (Figure 6d, 6f, 23	
Supplementary Fig 14b) by the engrafted cells; but also illustrated the 24	
16	
	
presence of mouse stromal and endothelial cells (Supplementary Fig 14b). 1	
Moreover, we observed minimal apoptosis and proliferation in the 2	
transplanted tubes 1 month after transplantation, confirming the stability and 3	
integrity of the reconstituted biliary epithelium (Supplementary Fig 14b-14c). 4	
Lumen patency was further confirmed by Fluorescein Isothiocyanate (FITC) 5	
cholangiogram, MRCP and serum cholestasis marker measurements (Figure 6	
6g, Supplementary Fig 14e-14f, Supplementary video 3). Accordingly animals 7	
receiving ECO-populated tubes exhibited no elevation in serum cholestasis 8	
markers (Bilirubin, ALP; Supplementary Fig 14e) and a patent lumen on 9	
imaging (Figure 6g, Supplementary Fig 14f); while the bio-artificial common 10	
bile ducts retained their ALP activity in vivo (Figure 6h).  11	
On the contrary, all fibroblast-populated collagen tubes failed due to lumen 12	
occlusion (Figure 6b-6c, 6e-6g, Supplementary Fig 14d), resulting in high 13	
biliary pressures and bile leak through the site of anastomosis (Figure 6b). In 14	
conclusion, our results demonstrate the capacity of ECO-populated collagen 15	
tubes to replace the native CBD in vivo.  16	
 17	
Discussion 18	
We have demonstrated that epithelial cells from the extrahepatic biliary tree 19	
can be expanded and propagated in vitro while maintaining their 20	
cholangiocyte transcriptional signature and functional characteristics. In 21	
addition, our results show that primary cholangiocytes expanded in vitro as 22	
organoids have a unique potential for organ regeneration. Indeed, our system 23	
provides the first proof-of-principle for the application of regenerative medicine 24	
17	
	
in the context of common bile duct pathology. The capacity to replace a 1	
diseased common bile duct with an in vitro bio-engineered ECO-tube could 2	
have a considerable impact for the management of disorders such as biliary 3	
atresia, which constitutes the leading cause for pediatric liver transplantation1; 4	
or ischemic strictures which are one of the most common complications 5	
following transplantation3. Consequently ECO-populated scaffolds constitute a 6	
novel system with high clinical relevance in the field of cholangiopathies. 7	
Furthermore, studies of the extrahepatic biliary epithelium have been limited 8	
by technical challenges in long-term culture and large-scale expansion of 9	
primary cholangiocytes. These challenges have so far precluded large scale 10	
experiments such as transcriptomic and genome-wide analyses which are 11	
urgently needed to better understand bile duct diseases, such as PSC and 12	
cholangiocarcinoma. The capacity of ECOs for large scale expansion, could 13	
address this challenge. Indeed, we demonstrate that starting from 105 14	
extrahepatic cholangiocytes we can generate between 1020 – 1025 cells after 15	
20 passages. Therefore, ECOs not only represent a novel source of cells for 16	
cell based therapy but also provide a unique model system for studying the 17	
physiology and modeling disorders of the extrahepatic biliary tree in vitro. 18	
Access to human tissue constitutes a considerable limitation for systems 19	
based on primary cells. However, we show that ECOs can be obtained not 20	
only from the common bile duct but also from the gallbladder. Gallbladder 21	
tissue is easily accessible and routinely discarded following liver 22	
transplantation and cholecystectomy, one of the most common surgical 23	
procedures performed. Furthermore, in individuals not having surgery the 24	
common bile duct can be accessed using minimally invasive procedures, such 25	
18	
	
as Endoscopic Retrograde Cholangio-Pancreatography (ERCP) and we 1	
demonstrate that cholangiocytes can be obtained through brushings, which 2	
are routinely performed to acquire histology specimens. Notably, no 3	
morphological or functional differences were observed between organoids 4	
obtained with these different methods. Moreover, due to the scalability of our 5	
system only a small amount of starting material is required. Finally, recent 6	
progress in replacing Matrigel by custom made hydrogels to grow gut 7	
organoids25 suggest that translating our system from Matrigel to Good 8	
Manufacturing Practice (GMP) could be feasible. Considered together, these 9	
approaches effectively address challenges of tissue availability and open the 10	
possibility of autologous as well as allogeneic cell based therapy.  11	
Notably, the derivation of primary hepatic stem cells using an organoid culture 12	
system has been reported previously12. However, the capacity of the resulting 13	
cells to differentiate into functional cholangiocytes and populate the biliary tree 14	
in vivo remains to be demonstrated. Furthermore, in vivo applications of such 15	
platforms could be restricted by contaminating stem cells with a capacity to 16	
proliferate inappropriately after transplantation and/or differentiate into non-17	
biliary cell types. Despite the association between organoids and adult stem 18	
cells26, we never observed the expression of hepatocyte or pancreatic 19	
markers during our experiments either in vitro or after transplantation, 20	
suggesting that the differentiation capacity of ECOs is limited to their lineage 21	
of origin. Moreover, canonical WNT signaling, which is crucial for the 22	
expansion of adult stem cell organoids27 is blocked in our culture conditions 23	
through the use of DKK-1 and further studies may be required to fully 24	
elucidate the role of R-spondin in our system. Considered together, these 25	
19	
	
observations suggest that our culture system does not include a stem cell 1	
population. However, we cannot completely exclude that these cells could 2	
represent a biliary progenitor population based on their ability to self-3	
propagate and generate organoids from single cells.  4	
Our system provides proof-of-principle for the application of primary cells in 5	
regenerative medicine; however, the use of stem cells has been suggested as 6	
an alternative for cell based therapy. Although we have recently established a 7	
system for the generation of stem cell-derived cholangiocyte-like cells 8	
(CLCs)9, there are considerable differences between ECOs and CLCs that 9	
render ECOs better suited to regenerative therapies for extrahepatic biliary 10	
injury. CLCs correspond to intrahepatic cholangiocytes, while ECOs represent 11	
extrahepatic biliary epithelium. These two cell types are distinct in terms of 12	
embryological origin and disease involvement14. Furthermore, CLCs still 13	
express fetal markers and therefore are more immature compared to ECOs 14	
derived from primary cells9. Therefore, CLCs may require a period of 15	
adjustment and further maturation in vivo, while mature, functional cells, such 16	
as ECOs, are required for coping with biliary injury in the acute setting. 17	
Finally, although hIPSCs provide a very good source of cells capable of 18	
generating almost any tissue, fully differentiated CLCs cannot be expanded; 19	
initial derivation/characterization of hIPSC lines remains time consuming; 20	
while variability in capacity of differentiation still constitutes a challenge. ECOs 21	
can be derived in less than 24 hours with a very high efficiency and can be 22	
expanded for multiple passages without losing their original characteristics. 23	
Consequently, ECOs are comparable to CLCs in terms of scalability, while 24	
20	
	
their mature phenotype provides a unique advantage for regenerative 1	
medicine applications in the context of tissue repair. 2	
In conclusion, our results open up novel avenues for the use of extrahepatic 3	
primary biliary tissue as a novel platform for in vitro studies, disease modeling 4	
and cell based therapy applications. 5	
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Figure Legends 1	
 2	
Figure 1 3	
Derivation and characterization of Extrahepatic Cholangiocyte Organoids 4	
(ECOs). (a) Schematic representation of the method used for the derivation of 5	
ECOs. (b) Quantitative real time PCR (QPCR) confirming the expression of 6	
biliary markers in Passage 1 (P1), Passage 10 (P10) and Passage 20 (P20) 7	
ECOs compared to freshly isolated Primary Cholangiocytes (PC) and 8	
Embryonic Stem  (ES) cells used as a negative control, n=4 ECO lines. 9	
Center line, median; box, interquartile range (IQR); whiskers, range (minimum 10	
to maximum). Values are relative to the housekeeping gene 11	
Hydroxymethylbilane Synthase (HMBS) (c) Immunofluorescence (IF) 12	
analyses confirming the expression of biliary markers in ECO organoids. 13	
Scale bars: 100 μm. Single channel and higher magnification images are 14	
provided in Supplementary Fig 3. (d) Euclidean hierarchical clustering 15	
analysis comparing the transcriptome of primary cholangiocytes (Primary), 16	
passage 20 ECOs (ECO), hIPSC-derived intrahepatic cholangiocyte-like-cells 17	
(iChoLC), ES cells (ES) and hepatocytes (HEP). For each probe, standard 18	
scores (z-scores) indicate the differential expression measured in number of 19	
standard deviations from the average level across all the samples. Clusters of 20	
genes expressed in ECOs, primary cholangiocytes or both cell types are 21	
indicated. GO analyses for each cluster are provided in Supplementary Fig 22	
7e. The data corresponds to 3 ECO lines. 23	
 24	
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Figure 2 1	
Functional characterization of ECO organoids. (a) Fluorescence images 2	
demonstrating secretion of the MDR1 fluorescent substrate rhodamine 123 in 3	
the lumen of ECOs, which is inhibited by the MDR1 inhibitor verapamil. Scale 4	
bars: 100 μm. (b) Fluorescence intensity along the white line in (a). (c) Mean 5	
intraluminal fluorescence intensity normalized to background in freshly plated 6	
Primary Cholangiocytes (Rho PC), Passage 20 ECOs (Rho P20) and P20 7	
ECOs treated with verapamil (Ver). Error bars, Standard Deviation (SD); 8	
n=1565 measurements in total. Asterisks (****) indicate statistical significance 9	
(P<0.001, Kruskal-Wallis test with Dunn’s correction for multiple comparisons) 10	
(d) Luminal extrusion of the fluorescent bile acid CLF compared to controls 11	
loaded with FITC, confirming bile acid transfer. Scale bars: 100 μm. (e) 12	
Fluorescence intensity along the white line in (d). (f) Mean intra-luminal 13	
fluorescence intensity normalized over background, n=1947 total 14	
measurements. Error bars, SD; asterisks as in (c). (g) ALP staining of ECOs. 15	
Scale bars: Light microscopy: 500 μm, Whole well images: 1 cm. (h) Mean 16	
GGT activity of P20 ECOs vs. PCs; error bars, SD; n=3, asterisks as in (c); 17	
one-way ANOVA with Dunnett’s correction for multiple comparisons. (i,j)  18	
Mean diameter measurements (i) and live images (j) of ECOs treated with 19	
secretin or secretin and somatostatin, n=8. Error bars, SD; ***P<0.001; 20	
#P>0.05 (Kruskal-Wallis test with Dunn’s correction for multiple comparisons). 21	
(a-j) Data representative of 3 different experiments. 22	
 23	
Figure 3 24	
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ECOs dissociated to single cells (ECO-SCs) can populate biodegradable PGA 1	
scaffolds. (a,b) Photographs of a PGA scaffold before (a) and after (b) 2	
treatment with ECOs. Scale bars: 1 cm. (c) Light microscopy images of a 3	
PGA scaffold populated with ECO-SCs. Red arrowheads: Fully populated 4	
scaffold; black arrowheads: cells recruiting new PGA fibers; white 5	
arrowheads: PGA fibers. Scale bars: 100μm. (d) Confocal microscopy images 6	
demonstrating cell expansion at different time-points after seeding of GFP-7	
positive ECO-SCs on a PGA scaffold. White lines indicate the position of PGA 8	
fibers. Scale bars: 100μm. (e) IF demonstrating the expression of biliary 9	
markers and lack of EMT markers in ECO-SCs seeded on PGA scaffolds. 10	
Scale bars: 100 μm (f) QPCR analyses demonstrating the expression of 11	
biliary markers in ECOs before (ECOs) and after (scaffold) seeding on PGA 12	
scaffolds, n=4 ECO lines. Center line, median; box, interquartile range (IQR); 13	
whiskers, range (minimum to maximum). Values are relative to the 14	
housekeeping gene HMBS. (g) Mean ratio of CK7+/CK19+ and 15	
CK19+/Vimentin (VIM)+ cells in IF analyses similar to the image shown in (e). 16	
Error bars represent SD; n=6. **P<0.01 (Mann-Whitney test). (h) Mean GGT 17	
activity of ECO-SCs populating a PGA scaffold, n=4. Error bars represent SD. 18	
****P<0.001 (two-tailed t-test). (i) ALP staining of PGA scaffolds populated by 19	
ECO-SCs. Scale bars: 500μm. 20	
 21	
Figure 4 22	
Biliary reconstruction in an extrahepatic biliary injury (EHBI) mouse model 23	
using ECOs. (a) Schematic representation of the method used for biliary 24	
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reconstruction. (b) Kaplan–Meier survival analysis, demonstrating rescue of 1	
EHBI mice following biliary reconstruction with ECO-populated scaffolds. 2	
**P<0.01 (log-rank test). (c) Images of gallbladders reconstructed with 3	
acellular PGA scaffolds (scaffold only), PGA scaffolds populated with ECOs 4	
(transplanted) and native un-reconstructed gallbladder controls (not 5	
transplanted), demonstrating full reconstruction with ECO populated scaffolds. 6	
CD: cystic duct, CBD: common bile duct, CHD: common hepatic duct, F: 7	
fundus, A: anterior surface, P: posterior surface. Scale bars: 500 μm. (d) H&E 8	
staining of the reconstructed gallbladders. L: lumen. Scale bars: 100 μm (e) IF 9	
analyses demonstrating the presence of GFP-positive ECOs expressing 10	
biliary markers in the reconstructed gallbladders. L: lumen Scale bars: 100 11	
μm. Higher magnification images are provided in Supplementary Fig 12 (f,g) 12	
FITC cholangiogram (n=1) (f) and MRCP images (n=2) (g) of reconstructed 13	
(transplanted) vs. native control (not transplanted) gallbladders (GB) 14	
demonstrating a patent lumen and unobstructed communication with the rest 15	
of the biliary tree. Scale bars: 1 mm. 16	
 17	
Figure 5 18	
ECOs can populate densified collagen tubular scaffolds. (a) Schematic 19	
representation of the method used for the generation of densified collagen 20	
tubular scaffolds. (b) Image of a densified collagen construct prior to tube 21	
excision. Scale bar, 500 μm. (c) Maximum intensity projection image 22	
demonstrating a GFP+ ECO-populated tube after its generation. Scale bar; 30 23	
μm (d) Confocal microscopy image demonstrating lumen patency of an ECO-24	
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populated collagen tube. Scale bar; 30 μm. (e) Images of a near confluent 1	
GFP+ ECO-tube. Scale bar; 100 μm. (f) IF analyses demonstrating the 2	
expression of biliary markers by ECOs following the generation of ECO-tubes. 3	
Scale bar; 100 μm. (g) QPCR analyses demonstrating the expression of 4	
biliary markers before (ECOs) and after (Scaffold) the generation of ECO-5	
populated collagen tubes. ES cells are used as a negative control, n=4 ECO 6	
lines. Center line, median; box, interquartile range (IQR); whiskers, range 7	
(minimum to maximum). Values are relative to HMBS expression. (h, i) ECO-8	
tubes exhibit ALP (h) and GGT (i) activity. Scale bars, 500μm; MEFs, Mouse 9	
Embryonic feeders used as negative control; Scaffold, ECO-populated, 10	
densified collagen tubes; error bars, SD; n=3. 11	
 12	
Figure 6 13	
Bile duct replacement using ECO-populated densified collagen tubes. (a) 14	
Schematic representation of the method used. (b) Postmortem images of 15	
mice receiving ECO-populated collagen tubes (ECOs) vs. mice receiving 16	
fibroblast-populated tubes (fibroblasts). Bile flow results in yellow 17	
pigmentation of ECO-tubes. The white color of the fibroblast conduit 18	
combined with a dilated bile-filled (yellow color) Proximal Bile Duct (PBD) 19	
suggests luminal occlusion, resulting in bile leak (yellow peritoneal 20	
pigmentation; white dashed line). SC: Collagen tubes/scaffolds; DBD: Distal 21	
Bile Duct; scale bars 500 μm. (c) Images of a thin walled construct resembling 22	
the native bile duct in animals receiving ECO-populated tubes vs. a thickened 23	
construct with no distinguishable lumen in animals receiving fibroblast tubes. 24	
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Scale bars 500 μm. (d) QPCR using human-specific primers confirming the 1	
expression of biliary markers by transplanted ECO-populated tubes (ECOs in 2	
vivo) compared to cultured ECOs (ECOs in vitro) and mouse biliary tissue 3	
used as a negative control, n=4 technical replicates. Center line, median; box, 4	
interquartile range (IQR); whiskers, range (minimum to maximum). Values are 5	
relative to HMBS expression. (e) H&E staining demonstrating the presence of 6	
a biliary epithelium and a patent lumen in ECO-tubes but not fibroblast 7	
constructs. Scale bars 100 μm. (f) IF analyses demonstrating a GFP+/ CK19+ 8	
epithelium lining the lumen of ECO-constructs, vs. obliteration of the lumen by 9	
fibroblasts in fibroblast constructs. Scale bars 100 μm. (g) FITC 10	
cholangiogram, demonstrating lumen patency in ECO-tubes vs. lumen 11	
occlusion in fibro-constructs. Scale bars: ECO, 100 μm; Fibroblasts, 500 μm 12	
(h) ALP activity is observed only in ECO-tubes, but not in fibroblast 13	
constructs. Scale bars: ECO, 100 μm; Fibroblasts, 500 μm. 14	
  15	
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Online Methods 1	
Primary biliary tissue 2	
Primary biliary tissue (bile duct or gallbladder) was obtained from deceased 3	
organ donors from whom organs were being retrieved for transplantation. The 4	
gallbladder or a section of the bile duct was excised during the organ retrieval 5	
operation after obtaining informed consent from the donor’s family (REC 6	
reference numbers: 12/EE/0253, NRES Committee East of England - 7	
Cambridge Central and 15/EE/0152 NRES Committee East of England - 8	
Cambridge South). 9	
Isolation of primary cholangiocytes 10	
Excised bile duct segments were placed in a 10 cm plate and washed once 11	
with William’s E medium (Gibco, Life Technologies). A longitudinal incision 12	
was made along the wall of the excised bile duct segment exposing the lumen 13	
and 10-15 ml of William’s E medium were added to cover the tissue. The 14	
luminal epithelium was subsequently scraped off using a surgical blade, while 15	
submerged in medium. The supernatant was collected and the tissue and 16	
plate were washed 2-3 times with William’s E medium to harvest any 17	
remaining cells. The supernatant and washes were centrifuged at 444g for 4 18	
minutes. The pellet was washed with William’s E, re-centrifuged and the 19	
supernatant was discarded (Figure 1a). 20	
Excised gallbladders were placed in a 15 cm plate, a longitudinal incision was 21	
made along the wall of the excised gallbladder and the lumen was washed 22	
once with William’s E medium (Gibco, Life Technologies). Cholangiocytes 23	
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were isolated and harvested following the method described above 1	
(Supplementary Fig 3a). 2	
For isolation through brushings, an excised bile duct segment was placed in a 3	
10 cm plate and cannulated using an ERCP brush. The lumen was brushed 4	
10-20 times and the cells were harvested by washing the brush several times 5	
in a falcon tube containing 40-50 ml of William’s E medium (Supplementary 6	
Fig 3b).  7	
Generation and culture of ECOs 8	
Isolated primary cholangiocytes were centrifuged at 444g for 4 minutes and 9	
re-suspended in a mixture of 66% matrigel (BD Biosciences, catalogue 10	
number: 356237) and 33% William’s E medium (Gibco, Life Technologies) 11	
supplemented with 10mM nicotinamide (Sigma-Aldrich), 17mM sodium 12	
bicarbonate (Sigma Aldrich), 0.2mM 2-Phospho-L-ascorbic acid trisodium salt 13	
(Sigma-Aldrich), 6.3mM sodium pyruvate (Invitrogen), 14mM glucose (Sigma-14	
Aldrich), 20mM HEPES (Invitrogen), ITS+ premix (BD Biosciences), 0.1µM 15	
dexamethasone (R&D Systems), 2mM Glutamax (Invitrogen),100U/ml 16	
penicillin per 100μg/ml streptomycin, 20ng/ml EGF (R&D Systems), 500ng/ml 17	
R-Spondin (R&D Systems) and 100ng/ml DKK-1 (R&D Systems). The cell 18	
suspension was plated in 24-well plate format, at 50μl/well, so that a small 19	
dome of matrigel was formed in the centre of each well and then incubated at 20	
37oC for 10-30 minutes until it solidified. Subsequently, 1ml of William’s E 21	
medium with supplements was added. The culture medium was changed 22	
every 48 hours.  23	
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To split the cells, the matrigel was digested by adding Cell Recovery Solution 1	
(Corning) for 30 minutes at 4oC. The resulting cell suspension was harvested, 2	
centrifuged at 444g for 4 minutes, washed once with William’s E medium and 3	
re-suspended in 66% matrigel and 33% William’s E medium with 4	
supplements, as described above. 5	
All experiments were performed using passage 20 ECOs unless otherwise 6	
stated. 7	
Cell line identity 8	
Demographic data for donor corresponding to the each ECO lines is provided 9	
in supplementary table 1. Following derivation ECO lines were authenticated 10	
by matching their karyotype (Supplementary Fig. 4b) to the sex of the donor of 11	
origin. The lines were tested on a regular basis and found to be negative for 12	
mycoplasma contamination.  13	
Immunofluorescence, RNA extraction and Quantitative Real Time PCR 14	
IF, RNA extraction and QPCR were performed as previously described9. A 15	
complete list of the primary and secondary antibodies used is provided in 16	
supplementary table 3. A complete list of the primers used is provided in 17	
supplementary table 4.  18	
All QPCR data are presented as the median, interquartile range (IQR) and 19	
range (minimum to maximum) of four independent ECO lines unless 20	
otherwise stated. Values are relative to the housekeeping gene 21	
Hydroxymethylbilane Synthase (HMBS). 22	
All IF images were acquired using a Zeiss Axiovert 200M inverted microscope 23	
or a Zeiss LSM 700 confocal microscope. Imagej 1.48k software (Wayne 24	
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Rasband, NIHR, USA, http://imagej.nih.gov/ij) was used for image processing. 1	
IF images are representative of 3 different experiments. IF images of 2	
reconstructed gallbladder sections are representative of 5 different animals. 3	
Microarrays 4	
RNA for microarray analysis was collected from 3 different ECO lines (n=3). 65	
The RNA was assessed for concentration and quality using a SpectroStar 66	
(BMG Labtech, Aylesbury, UK) and a Bioanalyser (Agilent Technologies, 67	
Cheadle, UK). Microarray experiments were performed at Cambridge 68	
Genomic Services, University of Cambridge, using the HumanHT-12 v4 69	
Expression BeadChip (Illumina, Chesterford, UK) according to the 70	
manufacturer’s instructions. Briefly, 200ng of Total RNA underwent linear 71	
amplification using the Illumina TotalPrep RNA Amplification Kit (Life 72	
Technologies, Paisley, UK) following the manufacturer’s instructions. The 73	
concentration, purity and integrity of the resulting cRNA were measured by 74	
SpectroStar and Bioanalyser. Finally cRNA was hybridised to the HumanHT-75	
12 v4 BeadChip overnight followed by washing, staining and scanning using 76	
the Bead Array Reader (Illumina). The microarray data are available on 77	
ArrayExpress (Accession number: E-MTAB-4591). For reviewer access, 78	
please use the following login details Username: Reviewer_E-MTAB-4591 79	
Password: rtIImbi0 80	
Microarrays analysis 81	
Raw data was loaded into R using the lumi package from bioconductor28 and 82	
divided into subsets according to the groups being compared; only the 83	
samples involved in a given comparison are used. Subsets were then filtered 84	
to remove any non-expressed probes using the detection p-value from 85	
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Illumina. Across all samples probes for which the intensity values were not 1	
statistically significantly different (P>0.01) from the negative controls were 2	
removed from the analysis. Following filtering the data was transformed using 3	
the Variance Stabilization Transformation29 from lumi and then normalised to 4	
remove technical variation between arrays using quantile normalisation. 5	
Comparisons were performed using the limma package30 with results 6	
corrected for multiple testing using False Discovery Rate (FDR) correction. 7	
Finally the quality of the data was assessed along with the correlations 8	
between samples within groups. 9	
Probes differentially expressed between HEP and ECOs representing the 10	
aggregate transcriptional “signature” of ECOs were selected for Euclidean 11	
hierarchical clustering using Perseus software (MaxQuant). Standard scores 12	
(z-scores) of the log2 normalized probe expression values across the different 13	
conditions were calculated and used for this analysis. Heatmaps and Primary 14	
Component Analysis (PCA) plots were generated using the MaxQuant 15	
Perseus software (http://www.perseus-framework.org/)31. Functional 16	
annotation and gene ontology analyses were performed on the genes 17	
differentially expressed between PCs and ECOs (Figure 1d) using the 18	
NIAID/NIH Database for Annotation, Visualization and Integrated Discovery 19	
(DAVID) v6.8 (https://david.ncifcrf.gov/)32,33. 20	
Western Analysis 21	
Total protein was extracted with lysis buffer (50mM Tris pH 8, 150mM NaCl, 22	
0.1% SDS, 0.5% sodium deoxycholate, 1% Trition X-100 and protease and 23	
phosphatase inhibitors). Protein concentrations were determined by BCA 24	
Protein Assay Kit (Thermo Fisher Scientific) according to the manufacturer’s 25	
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instructions. Samples were prepared for Western blot by adding 1x NuPAGE 1	
LDS Sample Buffer with 1% β-mercaptoethanol and incubated for 5 minutes 2	
at 95°C. Protein (25 μg) was separated by 4-12% NuPAGE Bis-Tris protein 3	
gels (Invitrogen) and transferred onto PVDF membranes (Bio-Rad). Proteins 4	
were detected by probing with antibodies specific to Phospho-β-catenin 5	
(Ser33/37/Thr41) (Cell Signalling Technology), Active-β-catenin (Millipore), 6	
Total-β-catenin (R&D), α-tubulin (Sigma) followed by incubation with 7	
horseradish peroxidase anti-mouse, anti-goat or anti-rabbit secondary 8	
antibodies. Membranes were developed using Pierce ECL Western blotting 9	
substrate (Thermo Scientific) according to the manufacturer’s instructions. 10	
Rho Kinase activity analyses 11	
Rho Kinase activity was measured using a commercially available kit (Cell 12	
Biolabs, STA-416) according to the manufacturer’s instructions 13	
Flow cytometry analyses 14	
ECO organoids were harvested using Cell Recovery Solution (Corning) for 30 15	
minutes at 4oC, centrifuged at 444g for 4 minutes and dissociated to single 16	
cells using TrypLETM Express (Gibco).  The cells were subsequently fixed 17	
using 4% PFA for 20 minutes at 4oC. Cell staining and flow cytometry 18	
analyses were performed as previously described9,34. 19	
Karyotyping 20	
ECO organoids were harvested using Cell Recovery Solution (Corning), 21	
dissociated to single cells as described above, plated in gelatin coated plates 22	
and cultured using William’s E medium with supplements. When the cells 23	
were sub-confluent, usually after 72hrs, the cultures were incubated for 3-4 24	
hours with William’s E medium with supplements containing 0.1μg/ml 25	
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colcemid (Karyomax®, Gibco). The cells were then harvested using Trypsin-1	
EDTA (0.05%) (Gibco) for 4-5 minutes at 37oC, centrifuged at 344g for 5 2	
minutes and re-suspended in 5mls of KCl hypotonic solution (0.055M). The 3	
suspension was re-centrifuged at 344g for 5 minutes, 2 mls of a 3:1 100% 4	
methanol:glacial acetic acid solution were added and slides were prepared as 5	
previously described35 6	
Comparative Genomic Hybridization analyses 7	
Genomic DNA was labeled using the BioPrime DNA Labeling Kit (Invitrogen), 8	
according to the manufacturer’s instructions and samples were hybridised to 9	
Agilent Sureprint G3 unrestricted CGH ISCA 8x60K human genome arrays 10	
following the manufacturer’s protocol, as previously described36.  The data 11	
was analysed using the Agilent CytoGenomics Software. 12	
Rhodamine123 transport assay 13	
The Rhodamine 123 transport assay was performed as previously described9 14	
and images were acquired using a Zeiss LSM 700 confocal microscope. 15	
Fluorescence intensity was measured between the organoid interior and 16	
exterior and luminal fluorescence was normalized over the background of the 17	
extraluminal space. Each experiment was repeated in triplicate. Error bars 18	
represent SD.  19	
Cholyl-Lysyl-Fluorescein transport assay 20	
To achieve loading with Cholyl-Lysyl-Fluorescein (CLF, Corning 21	
Incorporated), ECO organoids were split in 5µM of CLF and incubated at 37oC 22	
for 30 minutes.  Images were acquired using a Zeiss LSM 700 confocal 23	
microscope and fluorescence intensity was measured between the organoid 24	
interior and exterior as described for the Rhodamine 123 transport assay. To 25	
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demonstrate that the changes in CLF fluorescence intensity observed were 1	
secondary to active export of CLF from the organoid lumen, the experiment 2	
was repeated with 5µM of unconjucated Fluorescein Isothiocyanate (FITC) 3	
(Sigma-Aldrich) as a control. Fluorescence intensity measurements were 4	
performed as described for the Rhodamine 123 transport assay. Each 5	
experiment was repeated in triplicate. Error bars represent SD.  6	
GGT activity 7	
GGT activity was measured in triplicate using the MaxDiscovery™ gamma-8	
Glutamyl Transferase (GGT) Enzymatic Assay Kit (Bioo scientific) based on 9	
the manufacturer’s instructions. Error bars represent SD.  10	
Alkaline Phosphatase staining 11	
Alkaline phosphatase was carried out using the BCIP/NBT Color 12	
Development Substrate (5-bromo-4-chloro-3-indolyl-phosphate/nitro blue 13	
tetrazolium) (Promega) according to the manufacturer’s instructions. 14	
Response to Secretin and Somatostatin 15	
Responses to secretin and somatostatin were assessed as previously 16	
described9. 17	
Generation of ECOs expressing Green Fluorescent Protein 18	
EGFP expressing VSV-G pseudotyped, recombinant HIV-1 lentiviral particles 19	
were produced with an optimized second generation packaging system by 20	
transient co-transfection of three plasmids into HEK 293T cells (ATCC CRL-21	
11268). EGFP expression is under control of a core EF1α-promoter. All 22	
plasmids were a gift from Didier Trono and obtained from addgene (pWPT-23	
GFP #12255, psPAX2 #12260, pMD2.G, #12259). Viral infection of organoids 24	
was performed as previously described37. Infected ECOs were expanded for 2 25	
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passages, harvested as described above for flow cytometry analyses and cell 1	
sorting by flow cytometry for GFP positive cells was performed. GFP 2	
expressing single cells were plated using our standard plating method and 3	
cultured in William’s E medium with supplements for 1-2 weeks until fully 4	
grown ECO organoids developed. 5	
Generation of ECO populated PGA scaffolds 6	
1mm thick PolyGlycolic Acid (PGA) scaffolds with a density of 50mg/cc were 7	
used for all experiments. Prior to seeding cells, the PGA scaffolds were pre-8	
treated with a 1M NaOH for 10-30 seconds washed 3 times, decontaminated 9	
in a 70% ethanol solution for 30 minutes and then air-dried for another 30 10	
minutes until all the ethanol had fully evaporated. All scaffolds were a gift from 11	
Dr Sanjay Sinha and obtained from Biomedical Structures (Biofelt). 12	
ECOs were harvested and dissociated to single cells as previously described 13	
for flow cytometry analyses. 5-10x106 cells were re-suspended in 100 μl of 14	
William’s E medium with supplements, seeded on a scaffold surface area of 15	
1cm2 and incubated at 37oC for 30-60 minutes to allow the cells to attach to 16	
the scaffold. The scaffolds were placed in wells of a 24-well plate and 17	
checked at regular intervals during this period to ensure the medium did not 18	
evaporate. If necessary, 10-20 μl of William’s E medium with supplements 19	
were added. After 1 hour, 2-3 mls of William’s E medium with supplements 20	
were added to the wells and the medium was changed twice weekly. 21	
Generation of densified collagen tubes 22	
Densified collagen tubes were prepared using a novel approach. A 3D printed 23	
chamber was fabricated, consisting of a funnel piece and a base plate. A 24	
250μm thick metallic wire was mounted into the base plate and fed through 25	
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the centre of the funnel. Absorbent paper towels were compacted between 1	
the two 3D printed parts, which were then screwed together. 5 mg mL-1 2	
collagen gel solution, loaded with cells, was poured into the funnel and gelled 3	
at 37ºC for 30 min. After that time, the screws were loosened and, by placing 4	
the 3D printed chambers at 37ºC for 2-4h, water was drawn out of the 5	
collagen gel. A cell-loaded densified collagen tube was thus formed with a 6	
250μm lumen and a wall thickness of 30-100 μm, determined by the duration 7	
of the drying phase. Upon removal from the chamber, the tube was trimmed 8	
for excess collagen and cut to the required length. 9	
Culture of Human Mammary Epithelial Cells (HMECs) 10	
HMECs and the required tissue culture consumables were purchased as a kit 11	
from Lonza (cat no. cat no. CC-2551B) and the cells were cultured according 12	
to the supplier’s instructions 13	
Animal experiments 14	
All animal experiments were performed in accordance with UK Home Office 15	
regulations (UK Home Office Project License numbers PPL 80/2638 and PPL 16	
70/8702).	Immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice which 17	
lack B, T and NK lymphocytes38 were bred in-house with food and water 18	
available ad libitum pre- and post-procedures. A mix of male and female 19	
animals were used, aged approximately 6-8 weeks. All the ECO-constructs 20	
used were populated with ECOs derived from the common bile duct.  21	
Generation of Extra-Hepatic Biliary Injury (EHBI) mouse model 22	
To generate a model of extrahepatic biliary injury, midline laparotomy was 23	
performed and the gallbladder was first mobilized by dividing the ligamentous 24	
attachment connecting its fundus to the anterior abdominal wall under 25	
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isoflurane general anesthesia. A longitudinal incision was then made along 1	
2/3 of the length of the gallbladder, from the fundus towards Hartmann’s 2	
pouch (neck of gallbladder).  3	
Biliary reconstruction in EHBI mice 4	
To reconstruct the gallbladder, a scaffold section measuring approximately 1 x 5	
1 mm (seeded with ECOs or without ECOs in controls) was sutured as a 6	
‘patch’ to close the defect using 4 – 6 interrupted 10’0 non-absorbable nylon 7	
sutures under 40x magnification. The laparotomy was closed in two layers 8	
with continuous 5’0 absorbable Vicryl sutures. The animals were given 9	
buprenorphine (temgesic 0.1 mg/kg) analgesia as a bolus and observed every 10	
15 minutes in individual cages until fully recovered. 11	
8 animals underwent biliary reconstruction using an ECO-populated scaffold. 12	
All animals survived up to 104 days without complications and were culled 13	
electively for further analyses. Two control experiments were performed, 14	
where the animals underwent biliary reconstruction using acellular scaffolds. 15	
Both animals died within 24 hours from bile leak, therefore no further control 16	
experiments were performed to minimize animal discomfort. 17	
Bile duct replacement 18	
The native common bile duct was divided and a short segment excised. The 19	
populated densified collagen tube was anastomosed end-to-end, using 20	
interrupted 10’0 nylon sutures, between the divided proximal and distal 21	
common bile duct. A length of 5’0 nylon suture material (diameter 100 µm) 22	
was inserted into the collagen tube and fed into the proximal and distal 23	
common bile duct to ensure patency of the lumen during the anastomosis. 24	
After the anastomosis was complete, the 5’0 suture was pushed into the 25	
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duodenum through the distal bile duct and was removed through an incision in 1	
the duodenum, which was then closed with interrupted 10’0 nylon sutures. 2	
Lumen patency was assessed at the time of transplantation through light 3	
microscopy and cannulation of the lumen with a 5’0 non-absorbable suture. 4	
Transplantation was abandoned as futile in case of fully occluded tubes due 5	
to cell infiltration. These events were considered construct/tube failure rather 6	
than surgical complications and therefore were not censored in the survival 7	
analysis. 8	
Bile duct ligation 9	
C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, 10	
ME). The mice were housed and bred in a Minimal Disease Unit at the animal 11	
facility at Oslo University Hospital, Rikshospitalet, Oslo. All experiments were 12	
performed on male mice between 8 and 12 weeks of age. A median 13	
laparotomy was performed, the common bile duct exposed and ligated close 14	
to the junction of the hepatic bile ducts. Sham operated mice underwent the 15	
same procedure without ligation. Serum was harvested after 5 days. Alanine 16	
transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase 17	
(ALP) were measured in serum using an ADVIA 1800 (Siemens) at The 18	
Central Laboratory, Norwegian School of Veterinary Science. All animal 19	
experiments were approved by the Norwegian Food Safety Authority (project 20	
license no FOTS 8210/15) and all animals received human care in line with 21	
"Guide for the Care and Use of Laboratory Animals" (National Institutes of 22	
Health Publication, 8th Edition, 2011). 23	
Blood sample collection 24	
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Blood was taken using a 23g needles directly from the inferior vena cava 1	
under terminal anaesthesia at the time the animals were electively culled and 2	
transferred into 1.5ml Eppendorf tubes for further processing. 3	
Blood sample processing 4	
The blood samples were routinely processed by the University of Cambridge 5	
Core biochemical assay laboratory (CBAL).	 All of the sample analysis was 6	
performed on a Siemens Dimension EXL analyzer using reagents and assay 7	
protocols supplied by Siemens. 8	
Light microscopy imaging 9	
Light microscopy images of excised reconstructed gallbladders were acquired 10	
using a Leica MZFLIII fluorescence dissecting microscope. The images are 11	
representative of 5 animals. 12	
Cryosectioning and Histology 13	
Excised gallbladders were fixed in 4% PFA, immersed in sucrose solution 14	
overnight, mounted in optimal cutting temperature (OCT) compound and 15	
stored at -80°C until sectioning. Sections were cut to a thickness of 10µm 16	
using a cryostat microtome and mounted on microscopy slides for further 17	
analysis 18	
Haematoxylin and Eosin (H&E) Staining 19	
H&E staining was performed using Sigma-Aldrich reagents according to the 20	
manufacturer’s instructions. Briefly, tissue sections were hydrated, treated 21	
with Meyer’s Haematoxylin solution for 5 minutes (Sigma-Aldrich), washed 22	
with warm tap water for 15 minutes, placed in distilled water for 30-60 23	
seconds and treated with eosin solution (Sigma-Aldrich) for 30-60 seconds. 24	
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The sections were subsequently dehydrated and mounted using the Eukitt® 1	
quick-hardening mounting medium (Sigma-Aldrich). Histology sections were 2	
reviewed by an independent histopathologist with a special interest in 3	
hepatobiliary histology (SD). 4	
TUNEL assay 5	
The TUNEL assay was performed using a commercially available kit (abcam, 6	
ab66110) according to the manufacturer’s instructions. 7	
Fluorescein Isothiocyanate (FITC) cholangiography 8	
In situ FITC cholangiography was performed in sacrificed animals after 9	
dissection of the gallbladder free from the adherent liver lobes, but before 10	
surgical interruption of the extrahepatic biliary tree. The distal bile duct was 11	
cannulated with a 23½ gauge needle and FITC injected retrogradely into the 12	
gallbladder and images taken under a fluorescent microscope. 13	
Magnetic Resonance Cholangio-Pancreatography (MRCP) 14	
Magnetic resonance cholangio-pancreatography was performed after sacrifice 15	
of the animals.	MRCP was performed at 4.7T using a Bruker BioSpec 47/40 16	
system. A rapid acquisition with relaxation enhancement sequence was used 17	
with an echo train length of 40 echoes at 9.5ms intervals, a repetition time of 18	
1000ms, field of view 5.84×4.18×4.18cm3 with a matrix of 256×180×180 19	
yielding an isotropic resolution of 230 µm. The actively-decoupled four-20	
channel mouse cardiac array provided by Bruker was used for imaging. 21	
For the second mouse imaged, for higher signal to noise ratio to give 22	
improved visualisation of the biliary ducts a two-dimensional sequence was 23	
used with slightly varied parameters (24 spaced echoes at 11ms intervals to 24	
give an effective echo time of 110ms; repetition time 5741ms; matrix size of 25	
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256×256; field of view of 4.33×5.35cm2 yielding a planar resolution of 1	
170×200µm2). Fifteen slices were acquired coronally through the liver and gall 2	
bladder with a thickness of 0.6mm. For this acquisition, a volume coil was 3	
used to reduce the impact of radiofrequency inhomogeneity. 4	
To examine the biliary ducts and gall bladder, images were prepared by 5	
maximum intensity projections. Structural imaging to rule out neoplastic 6	
growths was performed using a T1-weighted 3D FLASH (fast low-angle shot) 7	
sequence with a flip angle of 25°, repetition time of 14ms and an echo time of 8	
7ms. The matrix was 512×256×256 with a field of view of 5.12×2.56×2.56cm3 9	
for a final isotropic resolution of 100 µm. 10	
The MRCP images were reviewed by 2 independent radiologists with a 11	
special interest in hepatobiliary radiology (EMG, SU). 12	
Statistical analyses 13	
All statistical analyses were performed using GraphPad Prism 6. For small 14	
sample sizes where descriptive statistics are not appropriate, individual data 15	
points were plotted. For comparison between 2 mean values a 2-sided 16	
student’s t-test was used to calculate statistical significance. The normal 17	
distribution of our values was confirmed using the D'Agostino & Pearson 18	
omnibus normality test where appropriate. Variance between samples was 19	
tested using the Brown-Forsythe test. For comparing multiple groups to a 20	
reference group one-way ANOVA with Dunnett correction for multiple 21	
comparisons was used between groups with equal variance, while the 22	
Kruskal-Wallis test with Dunn’s correction for multiple comparisons was 23	
applied for groups with unequal variance. Survival was compared using log-24	
rank (Mantel-Cox) tests. Where the number of replicates (n) is given this 25	
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refers to ECO lines or number of different animals unless otherwise stated. 1	
Further details of the statistical analyses performed are provided in 2	
Supplementary table 5. 3	
For animal experiments, group sizes were estimated based on previous study 4	
variance. Final animal group sizes were chosen to allow elective culling at 5	
different time point while maintaining n>4 animals surviving past 30 days to 6	
ensure reproducibility. No statistical methods were used to calculate sample 7	
size. No formal randomization method was used to assign animals to study 8	
groups. However; littermate animals from a cage were randomly assigned to 9	
experimental or control groups by a technician not involved in the study. No 10	
animals were excluded from the analysis. No blinding was used when only 11	
one group of animals survived for radiology imaging. In cases, such as 12	
gallbladders reconstructed with fibroblasts vs. ECOs where more than one 13	
groups survived to be imaged, both radiologists reviewing the images (EG 14	
and SU) where blinded to the method of reconstruction.  15	
  16	
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